The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.
Coherus sells Sandoz its Lucentis biosimilar for $170M to focus on oncology assets
Coherus BioSciences is selling its FDA-approved ophthalmology biosimilar Cimerli — a copycat version of Roche’s Lucentis — to Sandoz for $170 million in cash to
January 23, 2024